Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

INTRODUCTION: This study outlined cemiplimab intravenous (IV) dosing strategy to move from body weight (BW)-based 3 mg/kg every-2-week (Q2W) dosing in first-in-human study (study 1423; NCT02383212) to fixed 350 mg every-3-week (Q3W) dosing, utilizing population pharmacokinetics (PopPK) modeling and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Main Authors: Paccaly, Anne J., Migden, Michael R., Papadopoulos, Kyriakos P., Yang, Feng, Davis, John D., Rippley, Ronda K., Lowy, Israel, Fury, Matthew G., Stankevich, Elizabeth, Rischin, Danny
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2021
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107152/
https://ncbi.nlm.nih.gov/pubmed/33768419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01638-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares